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Pulmonary tuberculosis is still a global public health threat. Despite all efforts at its containment, the scourge is 
still menacing especially in the rural communities and among HIV infected patients. This retrospective study was 
carried out to determine the case detection rate of pulmonary tuberculosis in a rural community hospital in 
Nigeria from 2001-2006. A total of 1219 suspected patients were tested for pulmonary tuberculosis by sputum 
smear stained by Ziehl-Neelsen technique. Out of this number, 350 (28.7%) were positive for Acid-Fast Bacilli 
including 198 males and 152 females. Also 235 of the sputum-smear positive patients were tested for the human 
immunodeficiency virus (HIV) antibodies by Immunocomb 11 HIV 1 & 2 Bispot and confirmed by Immunocomb 
11 HIV 1 & 2 Combfirm and HIV-1 Western Blot kit. Sixty three (26.8%) of the sputum-smear positive patients 
were co-infected with HIV.  
Two hundred and seventy (77.1%) of the AFB positive patients were treated under the Directly Observed 
Therapy-Short course, 201 of them (74.4%) completed the treatment, 39 (14.4%) defaulted, 30 (11.1%) died before 
the completion of the treatment, 195 of the patients were declared cured and 6 were declared failed. Case detection 
rates could be improved upon by providing culture facilities at the DOTS centers. Also efforts should be made to 
ensure that all positive cases are followed to a logical conclusion and that anti-retroviral drugs are provided for 
patients co-infected with HIV to reduce the mortality rate of pulmonary tuberculosis.        
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INTRODUCTION  
Despite the attention and financial resources it 
had attracted to itself over the years, pulmonary 
tuberculosis still remains a major global public 
health problem. Approximately 2 billion people 
(one third of the world’s population) are already 
infected with the TB bacillus (1). About 8.8 
million new TB cases were estimated in 2005; 7.4 
million in Asia and sub Sahara Africa. A total of 
1.6 million people die of TB including 195,000 
patients infected with HIV (1). 
The World Health Organization (WHO) 
declared tuberculosis a world emergency in 1993 
(2).  In 2006, Nigeria was ranked as having the 
fourth largest tuberculosis burden in the world 
out of 22 high burden countries (3). (India and 
China ranked first and second respectively (4)). 
Subsequently, the Federal Ministry of Health 
declared tuberculosis a national emergency. 
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In 2005 report, the TB incidence rate was stable 
or in decline in all six WHO regions, however, 
the total number of new TB cases was still rising 
slowly because the case-load continued to grow 
in Africa, Eastern Mediterranean and South-East 
Asia regions (5). The recommended strategy was 
for countries to strive to detect at least 70% of 
new smear-positive cases and ensure a total cure 
rate of at least 35% of these detected cases. To 
achieve this, WHO in 1994 recommended that 
the national TB programmes adopt the strategy 
of ‘Directly Observed Therapy Short course’ 
(DOTS) (1). The two most important, out of the 5 
main components of DOTS being ‘improved 
cases detection by sputum-smear microscopy of 
symptomatic patients and standardized short-
course chemotherapy to all sputum smears 
positive cases with direct observation of drug 
intake in at least the first 2 months of treatment’ 
(1). By 2004, 182 countries had adopted and 
were implementing DOTS in their National 
programme, and in 2005 it increased to 187 
countries (5). 
More than 90 million TB patients were reported 
to WHO between 1980-2005; 26.5 million 
patients were notified by DOTS programmes 
between 1995-2005, and 10.8million new smear-
positive cases were registered for treatment by 
DOTS programme between 1994 and 2004 (5). 
 Globally, WHO reported 2.3 million and 
2.1million new smear-positive case notifications 
and 60% and 65% new smear-positive case 
detections under DOTS in 2005 and 2006 
respectively (5). Under this report WHO 
reviewed the number of new smear-positive 
cases successfully treated under DOTS at 1.7 
million and 1.8 million in 2005 and 2006 
respectively.  
The proportion of HIV-positive people screened 
for TB rose from 8.8% in 2005 to 61% in 2006 and 
the number of TB cases found to be HIV positive 
rose from 0.083% in 2005 to 0.5% in 2006 (5). 
 Presently, above 89% of the world’s population 
lived in areas where DOTS is being 
implemented by public health services. Global 
data clearly indicates that most of the resource 
poor countries are facing some limitations in the 
implementation of their DOTS programmes (6).  
 
A number of factors contribute to the 
tuberculosis epidemic in various parts of the 
world. Severely deficient general healthcare 
infrastructure is the driving force. Among other 
factors, poverty (7), ignorance (2) and HIV co-
infection (8, 9, 10) stand out as the disturbing 
pre-disposing factors for the spread of 
tuberculosis. Previous studies have revealed 
that HIV infected patients have increased risk 
for reactivation of latent tuberculosis, of rapid 
progression to disease of a newly acquired 
infection, and of death from tuberculosis 
infection  (4, 12, 13, 14). The increase in the 
number of patients with HIV/TB co-infection 
has resulted in significant rise in the 
transmission of multidrug resistant 
Mycobacterium tuberculosis strains (15). 
The six principal components highlighted by the 
‘stop TB strategy’ (5), a new global vision 
include: addressing TB/ HIV co-infection, 
controlling and combating MDR-TB, 
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contributing to the strengthening of healthcare 
system, engaging all healthcare providers, 
empowering patients and, communities and 
enabling and promoting research. All efforts are 
geared towards improving overall global TB 
control and reduce morbidity and mortality 
particularly in rural communities such as the 
one under review.    
 
 Several studies in Nigeria in the past two 
decades have tried to present the picture of the 
tuberculosis situation in some cities of the 
country such as Portharcourt (16), Lagos (17, 18, 
19), Benin City (20), and Ibadan (21). These were 
studies based in urban cities. Reports of the TB 
situation in rural communities of the country 
with low socio-economic status and poor 
healthcare facilities, where majority of the 
patients reside, is scarce. 
Therefore, this study was designed to assess the 
extent of realization of the 2005 global targets of 
70% cases detection and 85% cure rate proposed 
by the WHO assembly in 2000 (22) in a rural 
community. From this point, we x-ray the need 
to brace-up to partner with WHO on the policies 
and strategies to address the major constraints 
towards achieving global TB control and the 
primary vision of the stop TB strategy “ the 
global plan to stop TB, 2006-2015” launched in 
Jan. 2006 (5).  
  MATERIALS AND METHODS 
THE STUDY AREA 
The assessment was conducted at Osina 
Community Hospital, a secondary healthcare 
facility located in Osina, Ideato North Local 
Government Area of Imo State. The hospital was 
the only Directly Observed Therapy Short 
course (DOTS) centre for tuberculosis in Ideato 
North and South LGAs and a few others nearby 
LGAs in Imo State as at the time of this study. 
The presence of German expatriate specialist 
medical officers from the inception of the 
hospital up to the late 90’s gave the hospital a 
wide scope of patient in-take from all over Imo 
State and the neighboring states of Abia, 
Anambra and Enugu. 
The DOTS centre commenced in 1996 and 
follows the guidelines of the National 
Tuberculosis/Leprosy Control Programme in 
conjunction with German Leprosy Relief 
Association (GLRA).  
 
THE PATIENTS 
All patients attending the out-patients 
department of the Osina Community Hospital 
with symptoms  of pulmonary disorders either 
as primary patients or referred  from other 
hospitals and clinics and whose 3 sputum (one 
spot and two other consecutive) samples were 
submitted to the lab for testing between Jan 2001 
to Dec. 2006 were assessed for this report. 
A total of 1219 patients were tested for 
pulmonary tuberculosis from January 2001 to 
December, 2006. 
 
METHOD OF TESTING 
Three sputum samples were collected from the 
patients according to the National Tuberculosis/ 
Leprosy Control Programme guidelines as 
follows: 1st spot sample on arrival at the 
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laboratory, 2nd early morning sample the next 
day and 3rd sample produced on submission of 
the 2nd sample. For follow-up laboratory testing 
of smear-positive patients on treatment, 2 
consecutive early morning sputum samples 
were collected. Smears of the samples were 
made according to standard procedures (23) and 
stained by Ziehl-Neelsen technique. The films 
were thoroughly examined under oil-immersion 
for the acid-fast bacilli. Patients were classified 
as smear-positive if at least 2 samples out of the 
3 examined were positive for AFB. Culture 
facilities for Mycobacterium sp were not available 
in the laboratory within this period of review. 
Patients who have only 1 smear-positive result 
were asked to repeat the test after a short while. 
Smear-positive patients were counseled by the 
medical officer to enroll in the NBTL/GLRA 
Directly Observed Therapy Short course (DOTS) 
which includes 2 months intensive phase and 6 
months continuation phase. Treatment followed 
the NBTL/ World Health Organization 
guidelines. 
Patients were re-tested in the laboratory for AFB 
at the end of the 2nd month, 5th month and 7th 
month respectively. Treatment outcome for each 
of the patients was recorded after the final AFB 
result and completion of the treatment. 
 
HUMAN IMMUNODEFICIENCY VIRUS 
(HIV) TESTING 
HIV testing was performed for some of the 
patients based on the selection criteria of the 
medical officer. A total of 235 sputum-smear 
positive patients were co-tested for HIV 
antibodies. Testing was performed using 
Immunocomb 11 HIV 1 & 2 Bispot (Orgenics, 
Israel) and confirmed by HIV-1 Western Blot kit 
(Epitope Inc, Beaverton, Oregon) and 
Immunocomb 11 HIV 1 & 2 Combfirm 
(Orgenics, Israel). 
No anti-retroviral drug (ARV) was provided in 
the treatment centre for HIV-infected Tb 
patients at the time of the study. With this 
period under review data for this retrospective 
study were gathered from the laboratory and 
clinical case notes of the patients respectively. 
 
RESULTS 
From January 2001 to December 2006, a total of 
1219 patients were tested for pulmonary 
tuberculosis by the Ziehl-Neelsen staining 
technique for acid fast bacilli. Out of this 
number, 350 (28.7%) were positive. This includes 
198 (56%) males and 152 (43%) females, male to 
female ratio 1.3:1. The year 2004 has the highest 
number of pulmonary tuberculosis patients, 
76(21.7%): 39 males and 37 females, followed by 
the year 2003 with 62 smear positive patients 
(17.7%): 31 males and 31 females. The year 2005 
had the least smear positive patients (43, 12.3%) 
(Table 1). Mean age of occurrence of pulmonary 
tuberculosis was 35.4 ± 14.7 years. Peak age 
frequency was in the age range 20 to 29 (108, 
30.9%). This was followed by the age range 30 to 
39 (91, 26%) as seen in table 2. 
 
A total of 235 sputum smear positive patients 






TABLE 1: SPUTUM SMEAR RESULTS AND TREATMENT OUTCOMES 
 
YEAR TOTAL NO     POSITIVE   NO           TREATMENT     CURED    FAILED          DEFAULTED                    DIED 
EXAMINED    M   F   T   TREATED   COMPLETED 
2001       414(34.0%)        35   24  59 42          31                31                0                             8                3 
2002       179(14.7%)        29   24  53 43          37                37                0                             2                4 
2003       162(13.3%)       31   31   62 48          35                    33                2                             7                6 
2004       219(18.0%)       39   37   76 59          41                40                1                             9                9 
2005       135(11.1%)        25   18  43 28          13                    12                1                           10                5 
2006       110(9.0%)         38   18  57 50          44                42                2                             3                3 
TOTAL     1219      198 152 350         270                      201                  195               6                           39                  30 
                                              (28.7%)       (77.1%)             (57.4%)           (55.7 %)          (1.7%)                  (11.1%         (8.6%) 
 M= male 
 F= female 
                  T= Total 
 
Of this, 63 (26.8%) were positive for HIV. There 
were more female HIV positive patients (34, 
54%) than males (29, 46%) Again, the year 2004 
had the highest HIV positive tuberculosis 
patients (20, 35.1%). There were more male HIV 
positive tuberculosis patients in the years 2001 
and 2006 and more females in 2002, 2003 and 
2005 (figure 1). Of the 350 sputum smear 
positive patients, 270 (77.1%) enrolled for the 
DOTS treatment while 80 (22.9%) did not show 
up despite extensive counseling by the medical 
officer. Out of the 270 patients that started the 
treatment, 201 (74.4%) completed the treatment.  
 
Of those that started the treatment, 39 (14.4%) 
defaulted and were lost in the study and 30 
(1.1%) of those that started the treatment died 
before completion of the treatment. Of the 201 
that completed the treatment, 195 (97%) were 
declared cured after follow-up sputum smear 
negative results  at the end of treatment while 6 
(3%) were declared failed following persistent 
sputum smear positive results at the end of the 
treatment period. Out of the 195 that were 
declared cured, 5 (2.6%) had under one year 
repeat episodes (i.e. presented back about a year 
later with recurrent sputum smear positive 
tuberculosis). 
 
TABLE 2: AGE DISTRIBUTION OF PULMONARY TUBERCULOSIS PATIENTS. 
 

















20-29 19 23 23 13 11 19 108 
30-39 13 13 17 23 12 13 91 
50-59 5 3 3 6 5 6 28 












FIGURE 1: MALE- FEMALE DISTRIBUTION  
                     OF HIV/TB CO-INFECTION 
 
DISCUSSION  
PTB detection rate of 28.7% was recorded in this 
study. This was detected by sputum smear. The 
WHO national case detection rate of pulmonary 
tuberculosis by sputum smear in Nigeria was 
27% in 2004. But it has been reported that 
pulmonary tuberculosis patients with less than 
104 bacilli/ml of sputum cannot be detected by 
smear AFB microscopy (24). Furthermore, this 
rate was detected among patients with 
symptoms of pulmonary disorders. A good 
number of latent and asymptomatic tuberculosis 
patients were left undetected. The male-to-
female ratio for pulmonary tuberculosis was 1.3: 
1. This correlates with the findings of Nwokoma 
in Portharcourt (16). Several other studies in the 
country have reported similar higher male 
pulmonary tuberculosis cases (17, 19) contrary 
to the findings at Ibadan where it was reported 
to be higher females than males (21). In the 6 
year period, the year 2004 had the highest 
number of tuberculosis patients (76, 21.7%). This 
was followed by the year 2003. A cursory look at 
the WHO data for Africa shows the same trend 
(3). The mean age of patients infected by 
tuberculosis in this study was 35.4± 14.7.  This 
falls between the age ranges discovered in Lagos 
(19) and Portharcourt (16). The peak age 
frequency was in the age range 20-29 followed 
by 30-39 years. This was the same peak age 
discovered in Ibadan (7) and closely related to 
the findings in Lagos (17) and Portharcourt (16) 
and  corroborates reports that majority of people 
affected by tuberculosis in the developing 
countries were below the age of 50 while those 
of the developed countries were above the age 
of 50 (17, 25) . 
Of the 350 smear-positive patients, 235 were 
tested for HIV infection. 63 (26.8%) of these were 
positive. This agrees with the WHO estimate 
that about 27% of tuberculosis patients in 
Nigeria were also co-infected with HIV (3), but 
below the reported finding in Malawi that 
nearly two-thirds of tuberculosis patients were 
HIV positive (9). However, the number of 
patients tested for HIV in this study depended 
on mere clinical presentations and not a routine 
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tested manifested AIDS symptoms. This method 
of selection is obviously a source of bias since 
high risk patients could have escaped the 
clinical acumen of the medical officer. The 
synergistic effect of HIV/TB co-infection has 
been on the increase and accounts for more 
deaths associated with tuberculosis. 
Unfortunately, in this TB treatment centre, as in 
many others within some region of Africa, no 
antiretroviral drug is provided for the HIV 
infected TB patients. This will definitely 
compromise the treatment of these patients and 
could even increase the potential for the 
transmission of multi-drug resistant (MDR) (10) 
and extensive drug resistant (XDR) (27) 
tuberculosis.  
As with the age distribution of tuberculosis 
patients in this study, most of the HIV infected 
TB patients were in the age range of 20-29 and 
30-39. These are the sexually active age groups 
which are known to be at high risk of HIV 
infection. Earlier studies have revealed that TB 
patients less than 50 years of age are more 
frequently HIV infected (26). There were more 
female HIV infected TB patients than males, the 
same trend that was reported in Lagos (17) and 
Benin City (20) and which the researcher in 
Benin City attributed to higher female sexual 
activities. The bio-anatomical nature of female 
genito- urinary system is also a contributing 
factor. 
Of the 350 sputum smear positive patients, 270 
(77.1%) enrolled for the DOTS treatment while 
80 (22.9%) absented after counseling. This is 
worrisome because these people went back into 
the community without receiving appropriate 
treatment and continued to shed the bacilli in 
the environment to the detriment of the general 
populace. Some of these patients erroneously 
believe that tuberculosis is ‘witchcraft’ or 
‘poison’ sent to them by their enemies, relatives 
or neighbors. They therefore go to seek 
‘solution’ from traditional medicine or ‘spiritual 
houses’. The proprietors of these non-scientific 
medicine centres give the patients false 
assurance of spontaneous cure after their rituals 
and prayers. One of such patients traced was 
even assured that the blood he was coughing 
out was a way of getting rid of the ‘poison’ he 
swallowed from his ‘wicked uncle’. However, 
this patient was abandoned by this ‘miracle 
worker’ when his condition worsened but after 
two months at the DOTS centre, he made a 
dramatic recovery. Many of this kind of case 
abound in these rural communities and some 
could not muster the courage to come back to 
the hospital after their initial refusal of 
treatment, unless compelled by some 
enlightened relative or friends for the fortunate 
ones. Some come when it was too late owing to 
ignorance. 
Furthermore, out of the 270 patients that started 
the DOTS treatment, 201 (74.4%) completed the 
approved treatment regiment, 39 (14.4%) 
defaulted (abandoned the treatment) and were 
lost in the study. This could be as a result of the 
tendency among many patients especially the 
less informed in the rural communities to 
abandon treatment once their health seemed to 
have improved. Some of these patients could 
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also have died without proper document. The 
defaulter-retrieval function of the local 
government Tb supervisor is not sincerely done 
due to dereliction of duty by the officer 
concerned or as a result of paucity of funds, or 
because the patients or their relatives do not 
give correct and detailed contact addresses,  or 
the patient may have relocated.  
Of those that started the treatment, 30 (11.1%) 
died before the completion of the treatment. 
This could be as a result of the delay by patients 
in seeking medical attention at the onset of the 
symptoms. The non inclusion of antiretroviral 
drugs to the treatment regimen of the HIV 
infected Tb patients could also have caused the 
death of some of the patients as some of the 
dead were HIV positive.  
Out of the 201 patients that completed the 
treatment, 195 (97%) were declared cured. This 
is better than the reported success rates in 
Nigeria of 79% between 2001 and 2002, 59% in 
2003 (3) and the WHO target of 85% in Nigeria 
at these periods.  
Six patients (3%) out of those that completed the 
treatment were declared failed. These could be 
patients infected with multidrug resistant 
(MDR) and extensive drug resistant (XDR) 
strains of Mycobacterium tuberculosis (10, 27), 
although there is presently no scientific report 
on MDR/XDR in Nigeria to the knowledge of 
these authors.  
Furthermore, 5 patients (2.6%) of those that were 
declared cured had repeated episodes. This is 
quite alarming and could be endogenous 
reactivation of the previous tuberculosis or 
exogenous re-infection of the patient (28). 
Previous studies have noted that patients cured 
of Tb infection by one strain of Mycobacterium 
tuberculosis could be re-infected by another 
strain as the immunity by the primary strain 
does not protect the patient against a later 
infection by another strain (3). Rate of re-
infection has been reported to be higher than 
that of new infections in South Africa (29).  
RECOMMENDATION AND CONCLUSION 
From the results obtained in this study, it could 
be seen that the global targeted case detection 
and cure rates are achievable even in the rural 
areas with a little more efforts. An improvement 
in the case detection rate could be achieved by 
provision of culture facilities at the DOTS centre 
or at a nearby referral centre. Defaulter retrieval 
should be intensified through provision of 
adequate funds to provide incentives to local 
retrieval officer and to mobilize the patients to 
visit the clinic days this will save the community 
from being infected by fleeing infected patients 
who hide in the village and continue to shed the 
infective bacilli to the environment. 
Antiretroviral drugs must be provided for HIV 
infected Tb patients to reduce the death rate 
attributed to tuberculosis. Apart from the radio 
and television jingles on Tb, other means of 
enlightenment of the people in the rural areas 
should be adopted such as house to house 
visitation by the local authorities and rallies at 
the village squares to let the people know what 
tuberculosis is and what it is not in order to 
reduce morbidity, mortality and stigma 
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otherwise the global emergency is yet to 
commence.   
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